- Home
- FATE vs ZNTL Comparison
FATE vs ZNTL Comparison
Compare FATE & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FATE | ZNTL |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.8M | 118.3M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FATE | ZNTL |
|---|---|---|
| Price | $1.07 | $2.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $3.92 | ★ $5.87 |
| AVG Volume (30 Days) | ★ 1.5M | 1.4M |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,137,000.00 | ★ $26,865,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.66 | $1.01 |
| 52 Week High | $1.94 | $3.19 |
Technical Indicators
Market Signals| Indicator | FATE | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 90.72 |
| Support Level | $0.97 | $1.31 |
| Resistance Level | $1.13 | $1.46 |
| Average True Range (ATR) | 0.06 | 0.20 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 63.69 | 86.29 |
Price Performance
Historical ComparisonAbout FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.